These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 21205682

  • 1. Summary: Registry data.
    Bates D.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S39-41. PubMed ID: 21205682
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O.
    Ann Neurol; 2008 Jan 04; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [Abstract] [Full Text] [Related]

  • 10. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 12; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 11. [Interferon β].
    Matsushita T.
    Nihon Rinsho; 2015 Sep 12; 73 Suppl 7():196-204. PubMed ID: 26480700
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacologic management of multiple sclerosis.
    Blasier MG.
    Urol Nurs; 2008 Jun 12; 28(3):217-9. PubMed ID: 18605517
    [No Abstract] [Full Text] [Related]

  • 14. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [Abstract] [Full Text] [Related]

  • 15. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F, Kieseier BC.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract] [Full Text] [Related]

  • 16. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.
    Renoux C, Suissa S.
    Ann Neurol; 2008 Jul 01; 64(1):109-10; author reply 110. PubMed ID: 18668635
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interferon beta in multiple sclerosis: how much BENEFIT?
    Pittock SJ.
    Lancet; 2007 Aug 04; 370(9585):363-4. PubMed ID: 17678997
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.